Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 818

1.

Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.

Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B, Kattan MW, Zimmerman RS.

Cardiovasc Diabetol. 2018 Apr 10;17(1):54. doi: 10.1186/s12933-018-0699-7.

2.

Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study.

Saad M.

Ann Transl Med. 2018 Feb;6(3):55. doi: 10.21037/atm.2017.11.08. No abstract available.

3.

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.

Dekkers CCJ, Gansevoort RT, Heerspink HJL.

Curr Diab Rep. 2018 Mar 27;18(5):27. doi: 10.1007/s11892-018-0992-6. Review.

4.

Anti-diabetic medications: How to make a choice?

Babiker A, Al Dubayee M.

Sudan J Paediatr. 2017;17(2):11-20. doi: 10.24911/SJP.2017.2.12. Review.

5.

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J.

J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. Review.

PMID:
29534825
6.

The effect of saffron (Crocus sativus L.) hydroalcoholic extract on metabolic control in type 2 diabetes mellitus: A triple-blinded randomized clinical trial.

Milajerdi A, Jazayeri S, Hashemzadeh N, Shirzadi E, Derakhshan Z, Djazayeri A, Akhondzadeh S.

J Res Med Sci. 2018 Feb 20;23:16. doi: 10.4103/jrms.JRMS_286_17. eCollection 2018.

7.

Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report.

Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, Takeda N, Horiuchi R, Utsunomiya K.

Cardiovasc Diabetol. 2018 Mar 7;17(1):36. doi: 10.1186/s12933-018-0683-2.

8.

Individual differences in regulatory mode moderate the effectiveness of a pilot mHealth trial for diabetes management among older veterans.

Dugas M, Crowley K, Gao GG, Xu T, Agarwal R, Kruglanski AW, Steinle N.

PLoS One. 2018 Mar 7;13(3):e0192807. doi: 10.1371/journal.pone.0192807. eCollection 2018.

9.

The Landscape of Diabetic Kidney Disease in the United States.

Duru OK, Middleton T, Tewari MK, Norris K.

Curr Diab Rep. 2018 Feb 19;18(3):14. doi: 10.1007/s11892-018-0980-x. Review.

10.

Self-management levels of diet and metabolic risk factors according to disease duration in patients with type 2 diabetes.

Cho S, Kim M, Park K.

Nutr Res Pract. 2018 Feb;12(1):69-77. doi: 10.4162/nrp.2018.12.1.69. Epub 2018 Jan 22.

11.

Plasma Connective Tissue Growth Factor (CTGF/CCN2) Levels Predict Myocardial Infarction in the Veterans Affairs Diabetes Trial (VADT) Cohort.

Hunt KJ, Jaffa MA, Garrett SM, Luttrell DK, Lipson KE, Lopes-Virella MF, Luttrell LM, Jaffa AA; VADT Investigators.

Diabetes Care. 2018 Apr;41(4):840-846. doi: 10.2337/dc17-2083. Epub 2018 Jan 30.

PMID:
29382658
12.

Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment.

Serhiyenko VA, Serhiyenko AA.

World J Diabetes. 2018 Jan 15;9(1):1-24. doi: 10.4239/wjd.v9.i1.1. Review.

13.

Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.

Røder ME.

Ther Adv Chronic Dis. 2018 Jan;9(1):33-50. doi: 10.1177/2040622317735283. Epub 2017 Nov 9. Review.

14.

Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.

Hayes MJ, Kaestner V, Mailankody S, Prasad V.

CMAJ Open. 2018 Jan 15;6(1):E31-E38. doi: 10.9778/cmajo.20170088.

15.

KDM3A inhibition attenuates high concentration insulin‑induced vascular smooth muscle cell injury by suppressing MAPK/NF‑κB pathways.

Zhang BF, Jiang H, Chen J, Guo X, Hu Q, Yang S.

Int J Mol Med. 2018 Mar;41(3):1265-1274. doi: 10.3892/ijmm.2017.3351. Epub 2017 Dec 29.

16.

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

Gupta V, Canovatchel W, Lokesh BN, Santani R, Garodia N.

Indian J Endocrinol Metab. 2017 Nov-Dec;21(6):909-918. doi: 10.4103/ijem.IJEM_85_17. Review.

17.

Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.

Srivastava PK, Pradhan AD, Cook NR, Ridker PM, Everett BM.

J Am Heart Assoc. 2017 Dec 23;6(12). pii: e007268. doi: 10.1161/JAHA.117.007268.

18.

The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.

Nasrallah MP, Abi Khalil C, Refaat MM.

Biomed Res Int. 2017;2017:9257930. doi: 10.1155/2017/9257930. Epub 2017 Nov 14. Review.

19.
20.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

PMID:
29263194

Supplemental Content

Support Center